Clinical Report: Can Drying Drive TB Drug Resistance?

Overview

Desiccation of Mycobacterium tuberculosis resulted in increased rifampin-resistant bacteria, suggesting that drying during aerosol formation may influence genetic diversity and resistance mutations.

Background

Tuberculosis (TB) remains a significant global health threat, with rising cases of drug-resistant TB complicating treatment efforts. Understanding the mechanisms behind drug resistance is crucial for effective management and control of TB.

Data Highlights

The study demonstrated that desiccation increased the frequency of rifampin-resistant colonies by 50 to 100 times compared to bacteria maintained in saline. Recovery conditions significantly affected resistance frequency, with growth restoration in nutrient-rich media altering the observed resistance rates.

Key Findings

• Desiccation caused DNA damage in Mycobacterium tuberculosis, leading to a distinct stress response.
• Rifampin-resistant colonies emerged at a frequency 50 to 100 times higher in desiccated bacteria compared to those in saline.
• Silencing the mfd gene reduced rifampin resistance frequency and altered mutation patterns in rpoB.
• Recovery in nutrient-rich media before susceptibility testing significantly influenced resistance frequency.
• Among clinical isolates, the H445Y mutation was more common in strains with nonsynonymous mfd mutations compared to the overall rifampin-resistant dataset.

Clinical Implications

The findings suggest that environmental factors like desiccation may play a role in the emergence of drug-resistant TB strains. Clinicians should consider the implications of bacterial viability and resistance patterns in the context of TB transmission and treatment.

Conclusion

This study underscores the complex relationship between environmental stressors and the genetic evolution of drug resistance in Mycobacterium tuberculosis, warranting further research into the implications for TB transmission and treatment strategies.

Related Resources & Content

1. The Journal of Infectious Diseases, 2023 -- Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates
2. The Journal of Infectious Diseases, 2023 -- Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis
3. International Journal of Infectious Diseases, 2023 -- Treatment outcomes of high- and low-level isoniazid-resistant tuberculosis: Analysis from a Nationwide Pulmonary Tuberculosis Cohort
4. Infection, 2024 -- Cost-effective and precise identification of rifampicin and isoniazid resistance in tuberculosis sputum samples using multiplex PCR with multiple probes melting analysis
5. WHO Global Tuberculosis Report 2025 -- Global TB Report 2025 Factsheet
6. WHO, 2025 -- WHO announces landmark changes in treatment of drug-resistant tuberculosis
7. PubMed, 2023 -- Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and Disputed rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis
8. global-tb-report-2025_factsheet.pdf
9. WHO announces landmark changes in treatment of drug-resistant tuberculosis
10. Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and Disputed rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis - PubMed